Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01580618 · ClinicalTrials.gov registry record · Phase 2
Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy
A Phase 2 study, sponsored by Kaiser Permanente.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01580618 is a Phase 2 study that was terminated before completion, run by Kaiser Permanente. The registered enrollment target is 20 participants.
The verdict
NCT01580618, a Phase 2 study, was terminated before completion, sponsored by Kaiser Permanente.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The objective of the study is to determine the safety and efficacy of TNK infusion for the treatment of loculated pleural effusions in patients with known malignancy compared to normal saline infusion.
Interventions
- DRUG normal saline
- DRUG TNK (Tenecteplase)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01580618
The ClinicalTrials.gov registry entry for NCT01580618 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kaiser Permanente, which has 294 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which normal saline is the first listed.
NCT01580618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01580618 about?
NCT01580618 is a clinical study titled "Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy". The objective of the study is to determine the safety and efficacy of TNK infusion for the treatment of loculated pleural effusions in patients with known malignancy compared to normal saline infusion.
What is the current status of trial NCT01580618?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2008-01. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01580618?
The interventions under investigation include: normal saline (DRUG), TNK (Tenecteplase) (DRUG).
Who is sponsoring clinical trial NCT01580618?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.